Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Non-cash Items (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Non-cash Items readings, the most recent being $705000.0 for Q4 2024.

  • On a quarterly basis, Non-cash Items fell 41.05% to $705000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $705000.0, a 41.05% decrease, with the full-year FY2024 number at $5.2 million, up 337.44% from a year prior.
  • Non-cash Items hit $705000.0 in Q4 2024 for Unicycive Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $35.3 million in Q3 2023 to a low of $52000.0 in Q4 2022.
  • Median Non-cash Items over the past 3 years was $3.4 million (2023), compared with a mean of $6.8 million.
  • Biggest five-year swings in Non-cash Items: soared 2200.0% in 2023 and later crashed 86.74% in 2024.
  • Unicycive Therapeutics' Non-cash Items stood at $52000.0 in 2022, then soared by 2200.0% to $1.2 million in 2023, then crashed by 41.05% to $705000.0 in 2024.
  • The last three reported values for Non-cash Items were $705000.0 (Q4 2024), $4.7 million (Q3 2024), and $3.9 million (Q2 2024) per Business Quant data.